Attachment 4 - Sample Client Authorization Letter for Past Performance.pdf
PDF 96 KB Posted
- Solicitation number
- FDARFP1238397
About this file
This document includes a sample client authorization letter for past performance and information on a related federal contract opportunity. The sample letter is to be sent to clients requesting their participation in the evaluation of an entity's past performance as part of the response to Solicitation Number FDA-RFP-1238397. The solicitation is for the Transfusion-Transmissible Infections Monitoring System Laboratory & Risk Factor Database Coordinating Center being procured by the U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. Offerors are required to obtain letters from clients authorizing the use of past performance information and completed evaluation questionnaires are due no later than August 31, 2021. The solicitation seeks these services to support monitoring of transfusion-transmissible infections and related risk factors.
View the file
Other files
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
ATTACHMENT 4 – SAMPLE CLIENT AUTHORIZATION LETTER
FOR PAST PERFORMANCE
Solicitation Number: FDA-RFP-1238397
Dear Client, We are currently responding to Solicitation Number FDA-RFP-1238397 for the Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER) Transfusion-Transmissible Infections Monitoring System (TTIMS) Laboratory & Risk Factor Database Coordinating Center (LRCC).
The FDA placed emphasis on past performance as a key source selection factor and requiring that clients of entities responding to their solicitations be identified and their participation in the evaluation process be requested.
Therefore, enclosed is a Past Performance Evaluation Questionnaire for your completion.
We are requesting that you complete the questionnaire and send it via email to @fda.hhs.gov no later than 12:00 PM Eastern Time on August 31, 2021.
If you have questions regarding the attached questionnaire, or require assistance, please contact Howard Yablon, FDA Contract Specialist at 240-402-7630 or howard.yablon@fda.hhs.gov.
We thank you for your prompt response in this matter.
Sincerely, {Offering Entity} mailto:suzanne.martella@fda.hhs.gov mailto:howard.yablon@fda.hhs.gov
File details come from the government source that posted it. Updated .